Malgorzata Marjanska1, Stephen D. Weigand2, Geoffry L. Curran2, Thomas M. Wengenack2, Joseph F. Poduslo2, Michael Garwood1, Clifford R. Jack, Jr.2
1Radiology, University of Minnesota, Minneapolis, MN, United States; 2Mayo Clinic College of Medicine, Rochester, MN, United States
MRS was assessed as a non-invasive outcome measure capable of detecting metabolic alterations following passive immunization in a transgenic mouse model of Alzheimers disease (AD). Treatment of transgenic AD mice with either of two anti-A antibody regimes that have previously been demonstrated to reduce amyloid plaque load slowed the rate at which mIns normally increases in transgenic AD mice (APP-PS1) in a multi-dose treatment paradigm. 1H MRS may provide an in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies.